Technology ID
TAB-2406
Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies
E-Numbers
E-111-2012-0
Lead Inventor
Hennighausen, Lothar (NIDDK)
Applications
Research Materials
Therapeutic Areas
Oncology
Development Status
Pre-clinical
Lead IC
NIDDK
ICs
NIDDK
Selective inactivation of Stat1 in mammary cells indicates that its effect as a tumor suppressor in breast is direct.
STAT1 is considered a tumor suppressor, but it is not known if this effect occurs directly in mammary cells or secondarily by disrupting interferon signaling through the JAK/STAT1 pathway to induce immune responses. ERBB2/neu-induced breast cancer appeared sooner in mice lacking STAT1 only in mammary cells than in wild-type mice, indicating that STAT1 tumor suppression was intrinsic to mammary cells and not secondary to an induced immune response.
STAT1 is considered a tumor suppressor, but it is not known if this effect occurs directly in mammary cells or secondarily by disrupting interferon signaling through the JAK/STAT1 pathway to induce immune responses. ERBB2/neu-induced breast cancer appeared sooner in mice lacking STAT1 only in mammary cells than in wild-type mice, indicating that STAT1 tumor suppression was intrinsic to mammary cells and not secondary to an induced immune response.
Commercial Applications
Oncology
Immunology
Immunology
Licensing Contact: